BRCA1 and hyperinsulinemic hypoglycemia, familial, 4: The recent US Food and Drug Administration approval of drugs that target genetic results, such as poly(ADP-ribose) polymerase inhibitors for BRCA1/2 PV carriers with breast and other cancers (2,12,24-27) and immune checkpoint inhibitors for any advanced solid tumor with mismatch repair deficiency (28,29), offers strong evidence of benefit from genetic testing.